Jack Wallace
Stock Analyst at Guggenheim
(2.24)
# 2,460
Out of 4,829 analysts
22
Total ratings
54.55%
Success rate
5.04%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $241.44 | +3.13% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $0.38 | +1,478.95% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $55.21 | -69.21% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $4.52 | +209.73% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $156.13 | +40.91% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $26.05 | +53.55% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.21 | +1,286.96% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $23.01 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $241.44
Upside: +3.13%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $0.38
Upside: +1,478.95%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $55.21
Upside: -69.21%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $4.52
Upside: +209.73%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $156.13
Upside: +40.91%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $26.05
Upside: +53.55%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.21
Upside: +1,286.96%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $23.01
Upside: -